Patogenic Mutation in 5 Genes

Colorectal Cancer Clinical Trial

Official title:

Genomic Landscape of APC, KRAS, TP53, PIK3CA, and MLH1 in Colorectal

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04976439
• Other study ID #: MUTASICRC
• Status: Completed
• Start date: May 1, 2021
• Est. completion date: June 14, 2021

Study information

• Verified date: July 2021
• Source: Dr Cipto Mangunkusumo General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a pathogenic mutation profile of colorectal patients specifically in 5 genes, i.e. APC, TP53, PIK3CA, KRAS, and MLH1. Single nucleotide variants identified were synchronized with patients' characteristics.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: June 14, 2021
• Est. primary completion date: June 10, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• FFPE samples fullfilling purity criterion and pass quality control

Exclusion Criteria:

• none

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms
• KRAS Mutation-Related Tumors
• MLH1 Gene Mutation
• PIK3CA Gene Mutation
• TP53 Gene Mutation

Intervention

Other:
• co-occuring mutation
APC, TP53, PIK3CA, KRAS APC, TP53, PIK3CA, MLH1 APC, TP53, PIK3CA, KRAS, and MLH1 APC, TP53, PIK3CA

Locations

Country	Name	City	State
Indonesia	Vania Myralda Giamour Marbun	Jakarta	ALL

Sponsors (1)

Lead Sponsor	Collaborator
Dr Cipto Mangunkusumo General Hospital

Country where clinical trial is conducted

Indonesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Description of clinical characteristics	Age, gender	January 2017 - June 2021
Primary	Description of tumor nature	grade, stage, lymphovascular invasion, tumor location	January 2017 - June 2021
Primary	Description of survival	Median of life expectancy	January 2017 - June 2021